The news of the May 4 bidding and purchasing season of the medical website, the news of the success of haggling and the shortage of drugs in the provinces. There is concern, reducing the purchase price of drugs, and some of the drugs have been abandoned in local markets. Some of these companies have been particularly prominent in their unsolicited notice.
According to the statistics, in 2017, there are three manufacturers of five products, and the price is applied. Roche, cp, and a Belgian drug company.
It is not common for drug companies to reduce drug prices, but there are more examples.
In 2015, glaxo announced that it was cutting prices in some provinces by 20 to 30 percent. The lower price drugs are he puting, he weili and welled.
In July 2016, the price of the NWB injection was reduced from 9725 yuan to 7125 yuan in the yunnan bid, and the price cut was 2,600 yuan, or 26.7%.
On August 25, 2016, Shanghai roche pharmaceutical co., LTD. Announced that it will reduce the price of the targeted drug trokka, which is used to treat non-small cell lung cancer, by 30%.
The voluntary price cuts may be driven by market considerations. For example, it is a generic drug that is priced far lower than the original "gleevec". With the advantage of price, its market share has hit the market of the original medicine.
The price cut is 25 points, which reduces the pressure on patients and is expected to go further. This is the dominant trend in this year's sales, either by cutting prices or by cutting prices.
But outside the retail market, there is a rising voice. The next batch of drugs has been sold out, and the news of the rise has been sporadic in the media reports. When hospitals cut prices, the retail industry shouted "how the pharmacy will survive".
By contrast, the courts and retail markets are a bit of a backwater. However, when the price of drugs sold in the compound falls, it should bring down the price of similar products in the retail market.
Attached: the drug that applies for lower prices in 2017
